Notice for International Patients & Caregivers
English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.
Clinical Line Focus
Snapshot: 2026-09-04
Relapsed / Refractory Multiple Myeloma (RRMM) Trials Landscape
Relapsed/refractory multiple myeloma (RRMM) represents the largest proportion of active interventional clinical trials in China, featuring next-generation CAR-T, bispecific antibodies, ADCs, and novel small molecules.
As of 2026-09-04, there are 53 active interventional trials dedicated to this patient population in China.
Active Trials
53
Provinces
30
Centers
473
Clinical Characteristics & Guidance
For patients refractory to proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies, novel target clinical trials offer renewed avenues toward remission.
Screening criteria evaluate prior lines of therapy, refractoriness status, and vital organ function scores.
Leading Chinese medical centers possess extensive clinical expertise in managing specialized toxicities such as CRS and ICANS.
Active Studies (53)
Population synthesized by CMDNShowing 15 published English records of 53 registry trials.
Phase IIICTR20262221
RecruitingA Phase III, Randomized Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy (Including an Anti-CD38 Antibody and Lenalidomide)
Population: Relapsed/refractory
Target: Trispecific antibody targeting BCMA, GPRC5D, and CD3
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, CAMS)、The First Affiliated Hospital, Zhejiang University School of Medicine、Sun Yat-sen University Cancer Center、Shanghai Fourth People's Hospital 等 222 家中心
Phase IIICTR20253414
RecruitingA Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of SG301 Injection Combined with Pomalidomide and Dexamethasone Versus Placebo Combined with Pomalidomide and Dexamethasone in the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
Population: Relapsed/refractory
Target: Novel monoclonal antibody targeting CD38
Study Sites: The First Affiliated Hospital of Soochow University、Beijing Chaoyang Hospital, Capital Medical University、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Tianjin Medical University Cancer Institute & Hospital 等 78 家中心
Phase ITM20260016
RecruitingA Phase I Study of In Vivo CAR-T Therapy for Advanced Malignant Tumors (Multiple Myeloma, Lymphoma, Leukemia, Solid Tumors)
Population: Relapsed/refractory
Target: In situ (in vivo) CAR-T cell therapy targeting multiple targets including BCMA/GPRC5D/DLL3/FcRH5
Study Sites: Cancer Hospital, Chinese Academy of Medical Sciences
Phase IICTR20230238
RecruitingA Phase II, open-label, single-arm, multicenter clinical study evaluating the efficacy and safety of BCMA-targeted chimeric antigen receptor T-cell injection (CART-BCMA) in patients with relapsed/refractory multiple myeloma (RRMM)
Population: Relapsed/refractory
Target: BCMA-targeted chimeric antigen receptor T-cell (CAR-T) therapy
Study Sites: The First Affiliated Hospital, Zhejiang University School of Medicine、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Beijing Jishuitan Hospital、The Affiliated Hospital of Hebei University 等 25 家中心
Phase ICTR20243438
RecruitingA Phase I Clinical Study of CBG002 CAR-T Cell Injection in Patients with Relapsed or Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: BCMA-targeting CAR-T cell therapy
Study Sites: The First Affiliated Hospital, Zhejiang University School of Medicine、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Sun Yat-sen University Cancer Center
Phase I
RecruitingA Clinical Study on the Safety, Tolerability, and Preliminary Efficacy of CR-2011 in Relapsed/Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: In vivo chimeric antigen receptor T-cell (CAR-T) therapy targeting BCMA (based on mRNA-LNP technology)
Study Sites: Cancer Hospital Chinese Academy of Medical Sciences
Phase I/IICTR20254042
RecruitingA Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of HP-001 Capsules Combined with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: Small-molecule chemical drug
Study Sites: West China Hospital, Sichuan University、Henan Cancer Hospital、Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、The First Affiliated Hospital, Zhejiang University School of Medicine 等 20 家中心
Early Exploratory Clinical StudyNCT07622862
RecruitingAn Early Exploratory Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of BCMA/GPRC5D Dual-Targeted Allogeneic Universal CAR-T Cell Injection (DQ1001) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Population: Relapsed/refractory
Target: Allogeneic universal CAR-T targeting BCMA/GPRC5D
Study Sites: Zhongshan Hospital, Xiamen University
Phase ICTR20262569
RecruitingA Phase I Clinical Study Evaluating the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of 6MW5311 in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, and Multiple Myeloma
Population: Relapsed/refractory
Target: LILRB4 and CD3 bispecific antibody
Study Sites: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine、Henan Cancer Hospital、The First Affiliated Hospital, Zhejiang University School of Medicine、Shengjing Hospital of China Medical University 等 8 家中心
Phase I/IICTR20243384
RecruitingA Phase I/II, Multicenter, Open-Label Study of IBI3003 in Participants with Relapsed or Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: Trispecific antibody targeting GPRC5D, BCMA, and CD3
Study Sites: Zhongshan Hospital, Fudan University、Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology、The First Affiliated Hospital of Xi'an Jiaotong University、The Affiliated Hospital of Xuzhou Medical University 等 23 家中心
Phase INCT07620314
RecruitingAn Early Exploratory Clinical Study of the Safety and Efficacy of KSVCBD Injection in the Treatment of CD19- and/or BCMA-Positive B-Cell Malignancies
Population: Relapsed/refractory
Target: CD19, BCMA
Study Sites: Chinese PLA General Hospital (301 Hospital)
Phase Ib/IICTR20232814
RecruitingAn Open-Label, Multicenter Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of OriCAR-017 in Participants with Relapsed/Refractory Multiple Myeloma (MERCURY)
Population: Relapsed/refractory
Target: GPRC5D-targeted CAR-T
Study Sites: The First Affiliated Hospital, Zhejiang University School of Medicine、Shanghai Tongji Hospital、Jiangsu Province Hospital、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 等 8 家中心
Phase IIICTR20262035
RecruitingA Multicenter, Randomized, Controlled, Open-Label, Phase III Clinical Study of IBI3003 Versus Investigator's Choice of Regimen (DPd or PVd) on the Efficacy and Safety in Participants with Relapsed or Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: GPRC5D/BCMA/CD3 trispecific antibody
Study Sites: Zhongshan Hospital, Fudan University、The First Affiliated Hospital, Zhejiang University School of Medicine、Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology、The Affiliated Hospital of Xuzhou Medical University 等 45 家中心
Early exploratory clinical studyNCT07715630
RecruitingIn Vivo-Generated PICX Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
Population: Relapsed/refractory
Target: BCMA/CD70 CAR-T
Study Sites: The 920th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army
Phase ICTR20260125
RecruitingA Phase I, Open-label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HL17 in Participants with Relapsed or Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: Recombinant anti-BCMA and CD3 bispecific antibody injection
Study Sites: PKU Healthcare Luzhong Hospital